Skip to main content

What is LEUKOTAC®?

What is LEUKOTAC®?

LEUKOTAC® (inolimomab) is an immunotherapy monoclonal antibody that targets the interleukin-2 receptor (IL-2), a chemical molecule named cytokine that contributes to the development and proliferation of some white blood cells including T-cells responsible for aGvHD. By linking specifically to the α chain of the receptor (CD25), LEUKOTAC® prevents IL-2 from binding on the surface of the donor’s over-active T-cells which blocks their multiplication.

The efficacy of LEUKOTAC® in steroid-resistant aGvHD lies mainly in its specificity and its preferential affinity to the CD25 receptor found on the surface of T-lymphocytes.

Mode of action of LEUKOTAC®

Latest news on Leukotac

Discover our latest news regarding our pipeline, our partnerships and more

Thu, 04/05/2018 - 09:00
  • ELSALYS BIOTECH plans to submit to the European Medicines Agency before summer 2018 a Paediatric Investigation Plan (PIP) proposing to c

Thu, 03/15/2018 - 17:00
  • A poster summarising the safety profile results of the randomised Phase 3 testing LEUKOTAC® in patients with steroid-resistant acute gra

Thu, 10/12/2017 - 17:00
  • In a recent clinical study, it has shown a - favorable risk/benefit profile, supporting the experience already obtained with LEUKOTAC® i

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.